No patients in the standard dose group and 2 patients in the triple dose group reported secondary bacterial infections (bronchitis and sinusitis).The efficacy of oseltamivir in preventing naturally occurring influenza illness has been demonstrated in a post-exposure prevention study in households and two seasonal prevention studies.

Sorbitol may cause gastrointestinal discomfort and mild laxative effect.This medicinal product contains sodium benzoate. vertigo), Fatigue, Pyrexia, Pain in limbA total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza. Oseltamivir oral suspension should be prioritised for those unable to use capsules (as described below), such as for children under the age of 1 year. No effects on foetal development were observed. After reconstitution with 55 ml of water, the usable volume of oral suspension allows for the retrieval of a total of 10 doses of 30 mg oseltamivir. Whereas very high oral single doses of oseltamivir phosphate salt, up to the highest dose tested (1,310 mg/kg), had no adverse reactions in adult rats, such doses resulted in toxicity in juvenile 7-day-old rat pups, including death. When the neuramidases are blocked, the virus cannot spread. * Full genotyping was not performed in all studies.There has been no evidence for emergence of drug resistance associated with the use of Tamiflu in clinical studies conducted to date in post-exposure (7 days), post-exposure within household groups (10 days) and seasonal (42 days) prevention of influenza in immunocompetent patients. In children, the most commonly reported adverse reaction was vomiting. Oseltamivir works on the neuramidases of both influenza A (the most common type) and influenza B viruses.Tamiflu has been compared with placebo (a dummy treatment) in studies of the treatment of flu (2,413 patients aged 13 years or over, 741 elderly patients aged 65 years or over and 1,033 children aged between one and 12 years). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.Other drugs may interact with oseltamivir, including prescription and over-the-counter medicines, Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use oseltamivir only for the indication prescribed.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Copyright 1996-2020 Cerner Multum, Inc. Patients with hereditary fructose intolerance (HFI) should not take thismedicinal product.

Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. In addition, 245 immunocompromised patients (including 7 adolescents and 39 children) received Tamiflu for the treatment of influenza and 475 immunocompromised patients (including 18 children, of these 10 Tamiflu and 8 placebo) received Tamiflu or placebo for the prophylaxis of influenza.In adults/adolescents, the most commonly reported adverse reactions (ARs) were nausea and vomiting in the treatment studies, and nausea in the prevention studies.

No patients in the standard dose group and 2 patients in the triple dose group reported secondary bacterial infections (bronchitis and sinusitis).The efficacy of oseltamivir in preventing naturally occurring influenza illness has been demonstrated in a post-exposure prevention study in households and two seasonal prevention studies.

Sorbitol may cause gastrointestinal discomfort and mild laxative effect.This medicinal product contains sodium benzoate. vertigo), Fatigue, Pyrexia, Pain in limbA total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza. Oseltamivir oral suspension should be prioritised for those unable to use capsules (as described below), such as for children under the age of 1 year. No effects on foetal development were observed. After reconstitution with 55 ml of water, the usable volume of oral suspension allows for the retrieval of a total of 10 doses of 30 mg oseltamivir. Whereas very high oral single doses of oseltamivir phosphate salt, up to the highest dose tested (1,310 mg/kg), had no adverse reactions in adult rats, such doses resulted in toxicity in juvenile 7-day-old rat pups, including death. When the neuramidases are blocked, the virus cannot spread. * Full genotyping was not performed in all studies.There has been no evidence for emergence of drug resistance associated with the use of Tamiflu in clinical studies conducted to date in post-exposure (7 days), post-exposure within household groups (10 days) and seasonal (42 days) prevention of influenza in immunocompetent patients. In children, the most commonly reported adverse reaction was vomiting. Oseltamivir works on the neuramidases of both influenza A (the most common type) and influenza B viruses.Tamiflu has been compared with placebo (a dummy treatment) in studies of the treatment of flu (2,413 patients aged 13 years or over, 741 elderly patients aged 65 years or over and 1,033 children aged between one and 12 years). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.Other drugs may interact with oseltamivir, including prescription and over-the-counter medicines, Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use oseltamivir only for the indication prescribed.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Copyright 1996-2020 Cerner Multum, Inc. Patients with hereditary fructose intolerance (HFI) should not take thismedicinal product.

Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. In addition, 245 immunocompromised patients (including 7 adolescents and 39 children) received Tamiflu for the treatment of influenza and 475 immunocompromised patients (including 18 children, of these 10 Tamiflu and 8 placebo) received Tamiflu or placebo for the prophylaxis of influenza.In adults/adolescents, the most commonly reported adverse reactions (ARs) were nausea and vomiting in the treatment studies, and nausea in the prevention studies.

No patients in the standard dose group and 2 patients in the triple dose group reported secondary bacterial infections (bronchitis and sinusitis).The efficacy of oseltamivir in preventing naturally occurring influenza illness has been demonstrated in a post-exposure prevention study in households and two seasonal prevention studies.

Sorbitol may cause gastrointestinal discomfort and mild laxative effect.This medicinal product contains sodium benzoate. vertigo), Fatigue, Pyrexia, Pain in limbA total of 1473 children (including otherwise healthy children aged 1-12 years old and asthmatic children aged 6-12 years old) participated in clinical studies of oseltamivir given for the treatment of influenza. Oseltamivir oral suspension should be prioritised for those unable to use capsules (as described below), such as for children under the age of 1 year. No effects on foetal development were observed. After reconstitution with 55 ml of water, the usable volume of oral suspension allows for the retrieval of a total of 10 doses of 30 mg oseltamivir. Whereas very high oral single doses of oseltamivir phosphate salt, up to the highest dose tested (1,310 mg/kg), had no adverse reactions in adult rats, such doses resulted in toxicity in juvenile 7-day-old rat pups, including death. When the neuramidases are blocked, the virus cannot spread. * Full genotyping was not performed in all studies.There has been no evidence for emergence of drug resistance associated with the use of Tamiflu in clinical studies conducted to date in post-exposure (7 days), post-exposure within household groups (10 days) and seasonal (42 days) prevention of influenza in immunocompetent patients. In children, the most commonly reported adverse reaction was vomiting. Oseltamivir works on the neuramidases of both influenza A (the most common type) and influenza B viruses.Tamiflu has been compared with placebo (a dummy treatment) in studies of the treatment of flu (2,413 patients aged 13 years or over, 741 elderly patients aged 65 years or over and 1,033 children aged between one and 12 years). Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.Other drugs may interact with oseltamivir, including prescription and over-the-counter medicines, Remember, keep this and all other medicines out of the reach of children, never share your medicines with others, and use oseltamivir only for the indication prescribed.Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.Copyright 1996-2020 Cerner Multum, Inc. Patients with hereditary fructose intolerance (HFI) should not take thismedicinal product.

Date of first authorisation/renewal of the authorisationStart typing to retrieve search suggestions. In addition, 245 immunocompromised patients (including 7 adolescents and 39 children) received Tamiflu for the treatment of influenza and 475 immunocompromised patients (including 18 children, of these 10 Tamiflu and 8 placebo) received Tamiflu or placebo for the prophylaxis of influenza.In adults/adolescents, the most commonly reported adverse reactions (ARs) were nausea and vomiting in the treatment studies, and nausea in the prevention studies.